Innate Pharma (IPHA) Invested Capital (2017 - 2025)

Innate Pharma (IPHA) has disclosed Invested Capital for 8 consecutive years, with $33.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Invested Capital fell 22.84% year-over-year to $33.1 million, compared with a TTM value of $154.3 million through Dec 2024, up 11.12%, and an annual FY2024 reading of $33.5 million, down 22.26% over the prior year.
  • Invested Capital was $33.1 million for Q4 2024 at Innate Pharma, down from $42.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $43.1 million in Q4 2022 and bottomed at $17.7 million in Q4 2020.
  • Average Invested Capital over 5 years is $34.4 million, with a median of $35.2 million recorded in 2021.
  • The sharpest move saw Invested Capital crashed 93.12% in 2020, then surged 98.99% in 2021.
  • Year by year, Invested Capital stood at $17.7 million in 2020, then soared by 98.99% to $35.2 million in 2021, then increased by 22.55% to $43.1 million in 2022, then dropped by 0.43% to $42.9 million in 2023, then dropped by 22.84% to $33.1 million in 2024.
  • Business Quant data shows Invested Capital for IPHA at $33.1 million in Q4 2024, $42.9 million in Q4 2023, and $43.1 million in Q4 2022.